CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) encodes the p16 and p14ARF proteins, both of which are crucial in
regulating the cell cycle and maintaining genomic integrity. Loss of p16 function leads to unrestrained cyclin-dependent kinase activity, pushing cells through the cell cycle unchecked. Concurrently, loss of p14ARF disrupts the p53 pathway, further impairing the cellular capacity to undergo
apoptosis in response to stress, which facilitates early cancerous changes and progression. In pancreatic cancer, CDKN2A is one of the most frequently inactivated tumor suppressor genes, with somatic mutations or deletions present in over 90% of tumors. Germline mutations in CDKN2A are also associated with a significantly increased risk of developing pancreatic cancer. The loss of CDKN2A's protective functions allows pancreatic cells to accumulate further mutations and genomic instability, enabling the formation and progression of precancerous lesions into invasive pancreatic adenocarcinoma.
- CDKN2A c.71G>C / CDKN2A p.R24P: The CDKN2A R24P mutation results from a single nucleotide change (G to C) at position 71, causing an arginine to proline substitution at codon 24. Located in the functionally critical ankyrin repeat domain of p16, the R24P mutation disrupts p16's ability to bind and inhibit cyclin-dependent kinases CDK4 and CDK6. This loss of cell cycle regulation leads to uncontrolled cell division and increases susceptibility to pancreatic tumorigenesis.
- CDKN2A c.159G>C / CDKN2A p.M53I: The CDKN2A M53I mutation arises from a G to C transversion at nucleotide position 159, resulting in a methionine to isoleucine substitution at codon 53. Situated in the third ankyrin repeat of p16, the M53I mutation impairs p16's binding to CDK4/6 and its capacity to induce cell cycle arrest. Consequently, the M53I variant contributes to pancreatic cancer development by allowing unchecked cell cycle progression and proliferation.
- CDKN2A c.47T>G / CDKN2A p.L16R: The CDKN2A L16R mutation occurs due to a T to G transversion at nucleotide position 47, causing a leucine to arginine substitution at codon 16. The L16R mutation prevents normal folding of the p16 protein, leading to reduced expression and stability. Functionally, p16-L16R is unable to bind and inhibit CDK4/6, resulting in impaired cell cycle control. The presence of the L16R variant predisposes carriers to pancreatic cancer by diminishing p16's tumor suppressor activity and enabling unregulated cell division.